EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis

Trevor Griesman, Cynthia M McMillen, Seble Getenet Negatu, Jesse J Hulahan, Kanupriya Whig, Lenka Dohnalová, Mark Dittmar, Christoph A Thaiss, Kellie A Jurado, David C Schultz, Amy L Hartman, Sara Cherry iD

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1012343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Trevor Griesman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Rift Valley fever virus, Lipopeptides, Rift Valley Fever, Neurons. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rift Valley fever virus (RVFV) is an encephalitic bunyavirus that can infect neurons in the brain. There are no approved therapeutics that can protect from RVFV encephalitis. Innate immunity, the first line of defense against infection, canonically antagonizes viruses through interferon signaling. We found that interferons did not efficiently protect primary cortical neurons from RVFV, unlike other cell types. To identify alternative neuronal antiviral pathways, we screened innate immune ligands and discovered that the TLR2 ligand Pam 3 CSK 4 inhibited RVFV infection, and other bunyaviruses. Mechanistically, we found that Pam 3 CSK 4 blocks viral fusion, independent of TLR2. In a mouse model of RVFV encephalitis, Pam 3 CSK 4 treatment protected animals from infection and mortality. Overall, Pam 3 CSK 4 is a bunyavirus fusion inhibitor active in primary neurons and the brain, representing a new approach toward the development of treatments for encephalitic bunyavirus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rift Valley fever virusLipopeptidesRift Valley FeverNeuronsAnimalsMiceMice, Inbred C57BLHumansImmunity, InnateEncephalitis, ViralAntiviral Agents

Substanzen

LipopeptidesPam(3)CSK(4) peptideAntiviral Agents

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia Pennsylvania, United States of America.
  • Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Department of Infectious Diseases and Microbiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, United States of America.
  • Department of Microbiology, University of Pennsylvania, Philadelphia Pennsylvania, Unites States of America.
  • High throughput screening core, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

ORCID-Profile: Sara Cherry

Förderung

  • NIAID NIH HHS
  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • Burroughs Wellcome Fund

Zitieren

APA

Griesman, T., McMillen, C. M., Negatu, S. G., Hulahan, J. J., Whig, K., Dohnalová, L., Dittmar, M., Thaiss, C. A., Jurado, K. A., Schultz, D. C., Hartman, A. L., & Cherry, S. (2024). The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012343

Vancouver

Griesman T, McMillen CM, Negatu SG, Hulahan JJ, Whig K, Dohnalová L, et al. The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012343

BibTeX
@article{Griesman2024,
  author = {Griesman, Trevor and McMillen, Cynthia M and Negatu, Seble Getenet and Hulahan, Jesse J and Whig, Kanupriya and Dohnalová, Lenka and Dittmar, Mark and Thaiss, Christoph A and Jurado, Kellie A and Schultz, David C and Hartman, Amy L and Cherry, Sara},
  title = {The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1012343}
}
Kostenlos starten →